Conrad: the R&D is necessary right now to get the 2 major trials done.
1. TRIPP FX: first RCT of Oncosil combined with Folfirinox which is the standard of care for ca pancreas and
2. PANCOSIL: study of percutaneous delivered Oncosil
These are both underway and maybe a third recruited each. So there's some more R&D spend to come for this FY.
It would be great if Oncosil had more publicly funded trials but alas they don;t. The German trial, if it gets funded, will the first major publicly funded trial.
Conrad: the R&D is necessary right now to get the 2 major trials...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |